Publications by authors named "Rosa Alfaro Carrasco"
Article Synopsis
- SARS-CoV-2 may hinder a specific receptor in the body, and fenofibrate, which activates that receptor, was tested for its ability to reduce COVID-19 severity.
- A study involved 701 participants, giving some 145 mg of fenofibrate or a placebo for 10 days, measuring outcomes like death, hospitalization, and symptom severity.
- Results showed no significant difference between the fenofibrate and placebo groups in any key outcome, meaning fenofibrate didn't help in treating COVID-19.
Background Abnormal cellular lipid metabolism appears to underlie SARS-CoV-2 cytotoxicity and may involve inhibition of peroxisome proliferator activated receptor alpha (PPARα). Fenofibrate, a PPAR-α activator, modulates cellular lipid metabolism. Fenofibric acid has also been shown to affect the dimerization of angiotensin-converting enzyme 2, the cellular receptor for SARS-CoV-2.
View Article and Find Full Text PDF